View Future GrowthJS Link 과거 순이익 실적과거 기준 점검 0/6JS Link 의 수입은 연평균 -12.8%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 15.2%의 비율로 증가했습니다. 매출은 연평균 2.3%의 비율로 감소해 왔습니다.핵심 정보-12.80%순이익 성장률1.86%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률-2.32%자기자본이익률-17.64%순이익률-77.62%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Mar 22Full year 2024 earnings released: ₩542 loss per share (vs ₩323 loss in FY 2023)Full year 2024 results: ₩542 loss per share (further deteriorated from ₩323 loss in FY 2023). Revenue: ₩15.9b (down 28% from FY 2023). Net loss: ₩10.8b (loss widened 93% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.Reported Earnings • Mar 22Full year 2023 earnings released: ₩323 loss per share (vs ₩460 loss in FY 2022)Full year 2023 results: ₩323 loss per share (improved from ₩460 loss in FY 2022). Revenue: ₩21.9b (up 29% from FY 2022). Net loss: ₩5.60b (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 01Full year 2022 earnings released: ₩460 loss per share (vs ₩311 loss in FY 2021)Full year 2022 results: ₩460 loss per share (further deteriorated from ₩311 loss in FY 2021). Revenue: ₩17.0b (down 26% from FY 2021). Net loss: ₩7.78b (loss widened 53% from FY 2021). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • May 14+ 1 more updateJS Link, Inc. announced that it expects to receive KRW 25 billion in fundingJS Link, Inc. announced a private placement to issue Zero Coupon Series 17 Unregistered Interest Unsecured Private Convertible Bonds due June 10, 2029 for gross proceeds of KRW 25,000,000,000 on May 13, 2026. The transaction will include participation from new investor M Value Up No. 1 Fund. The transaction has been approved by shareholders, expected to close on June 10, 2026, matures on June 10, 2029, bears zero coupon rate, zero maturity rate, restricted to a hold period, 100% convertible into 601,742 shares at a fixed conversion price of KRW 41,546 from June 10, 2027 to May 10, 2029.공시 • Mar 17JS Link, Inc., Annual General Meeting, Mar 31, 2026JS Link, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 31, magokjungang 8-ro 3-gil, gangseo-gu, seoul South Korea공시 • Feb 04JS Link, Inc. announced that it has received KRW 20.00000805 billion in funding from Orbitech Co., Ltd., Joosung Sea & Air Co. LtdOn February 3, 2026, JS Link, Inc closed the transaction.분석 기사 • Jan 22JS Link, Inc. (KOSDAQ:127120) Stock Rockets 32% As Investors Are Less Pessimistic Than ExpectedJS Link, Inc. ( KOSDAQ:127120 ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 0.01% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.01% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).공시 • Oct 30JS Link, Inc. announced that it has received KRW 20.000005568 billion in funding from B & P Joosung Corp.On October 29, 2025, the JS Link, Inc closed the transaction.분석 기사 • Oct 10JS Link, Inc.'s (KOSDAQ:127120) 26% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, JS Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 26% in the...분석 기사 • Oct 10JS Link, Inc.'s (KOSDAQ:127120) Shares Climb 26% But Its Business Is Yet to Catch UpDespite an already strong run, JS Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 26% in the...공시 • Sep 23JS Link, Inc. announced that it expects to receive KRW 12 billion in fundingJS Link, Inc. announces a private placement with Rare Earth Mobility Fund to issue Bearer, unsecured, privately issued convertible bonds for gross proceeds of KRW 12,000,000,000 on September 22, 2025. Maturity date of the Notes is October 2, 2028. Interest rate of the Notes is 2%. and Expected closing date of the Notes is October 2, 2025. conversion price of the Notes is KRW 22,232.New Risk • Sep 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (32% increase in shares outstanding).공시 • Sep 17JS Link, Inc. announced that it expects to receive KRW 20.00000805 billion in fundingJS Link, Inc. announced a private placement to issue 1,308,045 common shares at an issue price of KRW 15,290 for gross proceeds of KRW 20,000,008,050 on September 15, 2025. The transaction includes participation from individual investor, Park Jin-soo. The transaction has been approved by the board of directors of the company. The payment date of the transaction is January 30, 2026. The transaction is subject to restrictions period of one year.공시 • Sep 03JS Link, Inc. announced that it has received KRW 7 billion in fundingOn September 3, 2025, JS Link, Inc. closed the transaction.분석 기사 • Aug 19Optimistic Investors Push JS Link, Inc. (KOSDAQ:127120) Shares Up 34% But Growth Is LackingKOSDAQ:A127120 1 Year Share Price vs Fair Value Explore JS Link's Fair Values from the Community and select yours...공시 • Aug 07JS Link, Inc. announced that it expects to receive KRW 8 billion in fundingJS Link, Inc. announced a private placement to issue 2% Series 15 Unregistered Interest Unsecured Private Convertible Bonds due September 3, 2028 for gross proceeds of KRW 8,000,000,000 on August 6, 2025. The transaction will include participation from new investors SA Value Up No. 3 Fund for KRW 5,000,000,000 and MG Value Up No. 3 Fund for KRW 3,000,000,000. The transaction has been approved by shareholders, expected to close on September 5, 2025, restricted to a hold period, bears 2% coupon rate, 6% maturity rate and matures on September 5, 2028, 100% convertible into 521,308 shares at a fixed conversion price of KRW 15,346 from September 03, 2026 to August 3, 2028.공시 • Aug 01JS Link, Inc. announced that it has received KRW 5.00000141 billion in funding from B & P Joosung Corp., Joosung Sea & Air Co. Ltd and other investorsOn July 31, 2025, JS Link, Inc. closed the transaction,공시 • Jul 23JS Link, Inc. announced that it expects to receive KRW 20.0000056 billion in fundingJS Link, Inc. announced a private placement to issue 1,742,768 common shares at an issue price of KRW 11,476 for gross proceeds of KRW 20,000,005,568 on July 21, 2025. The transaction will include participation from new investor Park Jin-soo. The transaction has been approved by shareholders, restricted to a hold period and expected to close on October 31, 2025.분석 기사 • Jul 05JS Link, Inc.'s (KOSDAQ:127120) Popularity With Investors Is Under Threat From OverpricingYou may think that with a price-to-sales (or "P/S") ratio of 21.2x JS Link, Inc. ( KOSDAQ:127120 ) is a stock to avoid...New Risk • Apr 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.공시 • Apr 17JS Link, Inc. announced that it has received KRW 10.00000107 billion in funding from Joosung Sea & Air Co. Ltd and other investorsOn April 16, 2025 JS Link, Inc. closed the transaction.공시 • Mar 28+ 1 more updateDNA Link, Inc. announced that it has received KRW 7.000002144 billion in funding from Joosung Sea & Air Co. LtdOn March 27, 2025, DNA Link, Inc. closed the transaction. The transaction included participation from returning investor Joosung Sea & Air Co. Ltd for 1,429,739 shares at an issue price of KRW 4,876 per share for the gross proceeds of KRW 7,000,002,144.공시 • Mar 27DNA Link, Inc. announced that it expects to receive KRW 5.00000141 billion in fundingDNA Link, Inc. announced a private placement to issue 810,373 common shares at an issue price of KRW 6,170 per share for gross proceeds of KRW 5,000,001,410 on March 26, 2025. The transaction will include participation from returning individual investor Park Jinsu. The transaction has been approved by shareholders, expected to close on July 31, 2025, restricted to a hold period.분석 기사 • Mar 26There's Reason For Concern Over DNA Link, Inc.'s (KOSDAQ:127120) Massive 29% Price JumpDNA Link, Inc. ( KOSDAQ:127120 ) shares have continued their recent momentum with a 29% gain in the last month alone...Reported Earnings • Mar 22Full year 2024 earnings released: ₩542 loss per share (vs ₩323 loss in FY 2023)Full year 2024 results: ₩542 loss per share (further deteriorated from ₩323 loss in FY 2023). Revenue: ₩15.9b (down 28% from FY 2023). Net loss: ₩10.8b (loss widened 93% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.공시 • Mar 13DNA Link, Inc., Annual General Meeting, Mar 26, 2025DNA Link, Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 31, magokjungang 8-ro 3-gil, gangseo-gu, seoul South Korea공시 • Jan 17DNA Link, Inc. announced that it has received KRW 3 billion in fundingOn January 15, 2025, the company has closed the transaction.New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩130.9b market cap, or US$89.6m).공시 • Dec 20DNA Link, Inc. announced that it expects to receive KRW 10.00000107 billion in funding from Joosung Sea & Air Co. LtdDNA Link, Inc. announced a private placement to issue 2,594,034 commons shares at an issue price of KRW 3,855 per share for the gross proceeds of KRW 10,000,001,070 on December 19, 2024. The transaction will include participation from new investor Joosung Sea & Air Co. Ltd. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on April 30, 2025.New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩94.3b market cap, or US$65.6m).New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩95.9b market cap, or US$67.4m).분석 기사 • Dec 04There's No Escaping DNA Link, Inc.'s (KOSDAQ:127120) Muted Revenues Despite A 27% Share Price RiseDespite an already strong run, DNA Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 27% in the...New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩92.2b market cap, or US$66.1m).공시 • Jul 31Entermedia Co.,Ltd. and Lee Jong Eun agreed to acquire 40% stake in National Bitumen Corporation from DNA Link, Inc. (KOSDAQ:A127120) for KRW 7.8 billion.Entermedia Co.,Ltd. and Lee Jong Eun agreed to acquire 40% stake in National Bitumen Corporation from DNA Link, Inc. (KOSDAQ:A127120) for KRW 7.8 billion on July 30, 2024. the consideration is in the form of 7th convertible bond of Orbitech held by the buyers. transaction is expected to complete on July 30, 2024.분석 기사 • Jul 12DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For GrowthDNA Link, Inc. ( KOSDAQ:127120 ) shares have had a really impressive month, gaining 27% after a shaky period...New Risk • Jun 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩6.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Minor Risks Shareholders have been diluted in the past year (9.3% increase in shares outstanding). Market cap is less than US$100m (₩48.0b market cap, or US$34.9m).Reported Earnings • Mar 22Full year 2023 earnings released: ₩323 loss per share (vs ₩460 loss in FY 2022)Full year 2023 results: ₩323 loss per share (improved from ₩460 loss in FY 2022). Revenue: ₩21.9b (up 29% from FY 2022). Net loss: ₩5.60b (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.분석 기사 • Mar 19There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is UndemandingYou may think that with a price-to-sales (or "P/S") ratio of 2.6x DNA Link, Inc. ( KOSDAQ:127120 ) is definitely a...공시 • Jan 25DNA Link, Inc. announced that it has received KRW 2 billion in funding from Orbitech Co., Ltd.On January 25, 2024, DNA Link, Inc. closed the transaction.공시 • Jan 22DNA Link, Inc. announced that it expects to receive KRW 2 billion in funding from Orbitech Co., Ltd.DNA Link, Inc. announces private placement of series 10 Domestic bearer interest-unsecured private placement convertible bonds for a principal amount of KRW 2,000,000,000 on January 22, 2024. The bonds will bear a surface interest rate of 2% and interest rate to maturity of 4% and will mature on January 25, 2027. The bonds will convertible into 617,283 shares of the company at conversion price of KRW 3,240 per share at a 100% conversion rate. The transaction will include participation from returning investor, Orbitech Co., Ltd.New Risk • Nov 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.1b free cash flow). Earnings have declined by 5.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.3% increase in shares outstanding). Market cap is less than US$100m (₩71.4b market cap, or US$55.0m).New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.1b free cash flow). Earnings have declined by 5.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩64.1b market cap, or US$48.4m).Reported Earnings • Apr 01Full year 2022 earnings released: ₩460 loss per share (vs ₩311 loss in FY 2021)Full year 2022 results: ₩460 loss per share (further deteriorated from ₩311 loss in FY 2021). Revenue: ₩17.0b (down 26% from FY 2021). Net loss: ₩7.78b (loss widened 53% from FY 2021). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.분석 기사 • Apr 19Is DNA Link (KOSDAQ:127120) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Feb 23Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last YearSome DNA Link, Inc. ( KOSDAQ:127120 ) shareholders are probably rather concerned to see the share price fall 66% over...Is New 90 Day High Low • Feb 17New 90-day low: ₩6,530The company is down 56% from its price of ₩14,850 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.Is New 90 Day High Low • Jan 27New 90-day low: ₩7,280The company is down 67% from its price of ₩21,750 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period.Is New 90 Day High Low • Jan 11New 90-day low: ₩7,740The company is down 71% from its price of ₩26,600 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 20% over the same period.Is New 90 Day High Low • Dec 09New 90-day low: ₩12,000The company is down 42% from its price of ₩20,700 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.공시 • Nov 27BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test act the Point of CareBASE10 Genetics and DNA Link announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings; Although Covid-19 deaths and new confirmed cases continue to rise across nursing homes in the US, many of those infected do recover. This has led to growing interest in the relationship between antibodies and their protective value whether generated by previous Covid-19 exposure or by a vaccine, once available.Is New 90 Day High Low • Nov 16New 90-day low: ₩14,000The company is down 21% from its price of ₩17,700 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day high: ₩24,700The company is up 267% from its price of ₩6,730 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.매출 및 비용 세부 내역JS Link가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A127120 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2620,307-15,76218,0276931 Dec 2519,316-16,44517,3662830 Sep 2516,139-12,41013,0701230 Jun 2515,061-14,62612,2801631 Mar 2514,273-15,15611,9461931 Dec 2415,908-10,80210,7561930 Sep 2419,042-11,3149,9822030 Jun 2419,110-6,9418,7532231 Mar 2421,046-4,2958,1701931 Dec 2321,949-5,5968,5748530 Sep 2318,947-6,4628,70021430 Jun 2318,718-5,7858,4954531 Mar 2317,427-5,6317,7416631 Dec 2216,981-7,7827,14146530 Sep 2219,141-7,0149,78851830 Jun 2221,999-5,78610,20770031 Mar 2223,186-7,52110,77079231 Dec 2122,992-5,10010,60353930 Sep 2119,730-9,6217,43263530 Jun 2116,660-12,3756,86276831 Mar 2115,903-13,1646,81566031 Dec 2015,286-13,0676,79846430 Sep 2015,654-14,56910,18525530 Jun 2016,208-13,24710,37612931 Mar 2015,333-12,61610,20135431 Dec 1915,573-13,1189,95535630 Sep 1914,397-5,3366,07136030 Jun 1913,331-5,7136,07134331 Mar 1914,300-4,9726,01212031 Dec 1814,876-3,7536,01010430 Sep 1814,860-2,5505,73541130 Jun 1815,135-8635,27440431 Mar 1814,819-234,65641131 Dec 1714,4803384,07653830 Sep 1714,888-2,9924,444-7430 Jun 1714,620-5,7415,04659931 Mar 1713,206-7,3245,01664031 Dec 1611,484-9,8115,39858530 Sep 1610,126-12,9385,5571,80930 Jun 168,869-11,3414,5611,14931 Mar 169,396-9,2834,58797431 Dec 159,420-9,0544,1711,02930 Sep 159,028-6,0184,2009230 Jun 159,305-5,3214,235204양질의 수익: A127120 은(는) 현재 수익성이 없습니다.이익 마진 증가: A127120는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A127120은 수익성이 없으며 지난 5년 동안 손실이 연평균 12.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A127120의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A127120은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(22.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A127120는 현재 수익성이 없으므로 자본 수익률이 음수(-17.64%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 03:13종가2026/06/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스JS Link, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Al Eum LeeiM SecuritiesSung Hwan ChoiKyobo Securities Co., LtdKidal BaeShinhan Investment Corp.
Reported Earnings • Mar 22Full year 2024 earnings released: ₩542 loss per share (vs ₩323 loss in FY 2023)Full year 2024 results: ₩542 loss per share (further deteriorated from ₩323 loss in FY 2023). Revenue: ₩15.9b (down 28% from FY 2023). Net loss: ₩10.8b (loss widened 93% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 22Full year 2023 earnings released: ₩323 loss per share (vs ₩460 loss in FY 2022)Full year 2023 results: ₩323 loss per share (improved from ₩460 loss in FY 2022). Revenue: ₩21.9b (up 29% from FY 2022). Net loss: ₩5.60b (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 01Full year 2022 earnings released: ₩460 loss per share (vs ₩311 loss in FY 2021)Full year 2022 results: ₩460 loss per share (further deteriorated from ₩311 loss in FY 2021). Revenue: ₩17.0b (down 26% from FY 2021). Net loss: ₩7.78b (loss widened 53% from FY 2021). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • May 14+ 1 more updateJS Link, Inc. announced that it expects to receive KRW 25 billion in fundingJS Link, Inc. announced a private placement to issue Zero Coupon Series 17 Unregistered Interest Unsecured Private Convertible Bonds due June 10, 2029 for gross proceeds of KRW 25,000,000,000 on May 13, 2026. The transaction will include participation from new investor M Value Up No. 1 Fund. The transaction has been approved by shareholders, expected to close on June 10, 2026, matures on June 10, 2029, bears zero coupon rate, zero maturity rate, restricted to a hold period, 100% convertible into 601,742 shares at a fixed conversion price of KRW 41,546 from June 10, 2027 to May 10, 2029.
공시 • Mar 17JS Link, Inc., Annual General Meeting, Mar 31, 2026JS Link, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 31, magokjungang 8-ro 3-gil, gangseo-gu, seoul South Korea
공시 • Feb 04JS Link, Inc. announced that it has received KRW 20.00000805 billion in funding from Orbitech Co., Ltd., Joosung Sea & Air Co. LtdOn February 3, 2026, JS Link, Inc closed the transaction.
분석 기사 • Jan 22JS Link, Inc. (KOSDAQ:127120) Stock Rockets 32% As Investors Are Less Pessimistic Than ExpectedJS Link, Inc. ( KOSDAQ:127120 ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...
New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 0.01% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.01% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
공시 • Oct 30JS Link, Inc. announced that it has received KRW 20.000005568 billion in funding from B & P Joosung Corp.On October 29, 2025, the JS Link, Inc closed the transaction.
분석 기사 • Oct 10JS Link, Inc.'s (KOSDAQ:127120) 26% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, JS Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 26% in the...
분석 기사 • Oct 10JS Link, Inc.'s (KOSDAQ:127120) Shares Climb 26% But Its Business Is Yet to Catch UpDespite an already strong run, JS Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 26% in the...
공시 • Sep 23JS Link, Inc. announced that it expects to receive KRW 12 billion in fundingJS Link, Inc. announces a private placement with Rare Earth Mobility Fund to issue Bearer, unsecured, privately issued convertible bonds for gross proceeds of KRW 12,000,000,000 on September 22, 2025. Maturity date of the Notes is October 2, 2028. Interest rate of the Notes is 2%. and Expected closing date of the Notes is October 2, 2025. conversion price of the Notes is KRW 22,232.
New Risk • Sep 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (32% increase in shares outstanding).
공시 • Sep 17JS Link, Inc. announced that it expects to receive KRW 20.00000805 billion in fundingJS Link, Inc. announced a private placement to issue 1,308,045 common shares at an issue price of KRW 15,290 for gross proceeds of KRW 20,000,008,050 on September 15, 2025. The transaction includes participation from individual investor, Park Jin-soo. The transaction has been approved by the board of directors of the company. The payment date of the transaction is January 30, 2026. The transaction is subject to restrictions period of one year.
공시 • Sep 03JS Link, Inc. announced that it has received KRW 7 billion in fundingOn September 3, 2025, JS Link, Inc. closed the transaction.
분석 기사 • Aug 19Optimistic Investors Push JS Link, Inc. (KOSDAQ:127120) Shares Up 34% But Growth Is LackingKOSDAQ:A127120 1 Year Share Price vs Fair Value Explore JS Link's Fair Values from the Community and select yours...
공시 • Aug 07JS Link, Inc. announced that it expects to receive KRW 8 billion in fundingJS Link, Inc. announced a private placement to issue 2% Series 15 Unregistered Interest Unsecured Private Convertible Bonds due September 3, 2028 for gross proceeds of KRW 8,000,000,000 on August 6, 2025. The transaction will include participation from new investors SA Value Up No. 3 Fund for KRW 5,000,000,000 and MG Value Up No. 3 Fund for KRW 3,000,000,000. The transaction has been approved by shareholders, expected to close on September 5, 2025, restricted to a hold period, bears 2% coupon rate, 6% maturity rate and matures on September 5, 2028, 100% convertible into 521,308 shares at a fixed conversion price of KRW 15,346 from September 03, 2026 to August 3, 2028.
공시 • Aug 01JS Link, Inc. announced that it has received KRW 5.00000141 billion in funding from B & P Joosung Corp., Joosung Sea & Air Co. Ltd and other investorsOn July 31, 2025, JS Link, Inc. closed the transaction,
공시 • Jul 23JS Link, Inc. announced that it expects to receive KRW 20.0000056 billion in fundingJS Link, Inc. announced a private placement to issue 1,742,768 common shares at an issue price of KRW 11,476 for gross proceeds of KRW 20,000,005,568 on July 21, 2025. The transaction will include participation from new investor Park Jin-soo. The transaction has been approved by shareholders, restricted to a hold period and expected to close on October 31, 2025.
분석 기사 • Jul 05JS Link, Inc.'s (KOSDAQ:127120) Popularity With Investors Is Under Threat From OverpricingYou may think that with a price-to-sales (or "P/S") ratio of 21.2x JS Link, Inc. ( KOSDAQ:127120 ) is a stock to avoid...
New Risk • Apr 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
공시 • Apr 17JS Link, Inc. announced that it has received KRW 10.00000107 billion in funding from Joosung Sea & Air Co. Ltd and other investorsOn April 16, 2025 JS Link, Inc. closed the transaction.
공시 • Mar 28+ 1 more updateDNA Link, Inc. announced that it has received KRW 7.000002144 billion in funding from Joosung Sea & Air Co. LtdOn March 27, 2025, DNA Link, Inc. closed the transaction. The transaction included participation from returning investor Joosung Sea & Air Co. Ltd for 1,429,739 shares at an issue price of KRW 4,876 per share for the gross proceeds of KRW 7,000,002,144.
공시 • Mar 27DNA Link, Inc. announced that it expects to receive KRW 5.00000141 billion in fundingDNA Link, Inc. announced a private placement to issue 810,373 common shares at an issue price of KRW 6,170 per share for gross proceeds of KRW 5,000,001,410 on March 26, 2025. The transaction will include participation from returning individual investor Park Jinsu. The transaction has been approved by shareholders, expected to close on July 31, 2025, restricted to a hold period.
분석 기사 • Mar 26There's Reason For Concern Over DNA Link, Inc.'s (KOSDAQ:127120) Massive 29% Price JumpDNA Link, Inc. ( KOSDAQ:127120 ) shares have continued their recent momentum with a 29% gain in the last month alone...
Reported Earnings • Mar 22Full year 2024 earnings released: ₩542 loss per share (vs ₩323 loss in FY 2023)Full year 2024 results: ₩542 loss per share (further deteriorated from ₩323 loss in FY 2023). Revenue: ₩15.9b (down 28% from FY 2023). Net loss: ₩10.8b (loss widened 93% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
공시 • Mar 13DNA Link, Inc., Annual General Meeting, Mar 26, 2025DNA Link, Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 31, magokjungang 8-ro 3-gil, gangseo-gu, seoul South Korea
공시 • Jan 17DNA Link, Inc. announced that it has received KRW 3 billion in fundingOn January 15, 2025, the company has closed the transaction.
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩130.9b market cap, or US$89.6m).
공시 • Dec 20DNA Link, Inc. announced that it expects to receive KRW 10.00000107 billion in funding from Joosung Sea & Air Co. LtdDNA Link, Inc. announced a private placement to issue 2,594,034 commons shares at an issue price of KRW 3,855 per share for the gross proceeds of KRW 10,000,001,070 on December 19, 2024. The transaction will include participation from new investor Joosung Sea & Air Co. Ltd. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on April 30, 2025.
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩94.3b market cap, or US$65.6m).
New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩95.9b market cap, or US$67.4m).
분석 기사 • Dec 04There's No Escaping DNA Link, Inc.'s (KOSDAQ:127120) Muted Revenues Despite A 27% Share Price RiseDespite an already strong run, DNA Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 27% in the...
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩92.2b market cap, or US$66.1m).
공시 • Jul 31Entermedia Co.,Ltd. and Lee Jong Eun agreed to acquire 40% stake in National Bitumen Corporation from DNA Link, Inc. (KOSDAQ:A127120) for KRW 7.8 billion.Entermedia Co.,Ltd. and Lee Jong Eun agreed to acquire 40% stake in National Bitumen Corporation from DNA Link, Inc. (KOSDAQ:A127120) for KRW 7.8 billion on July 30, 2024. the consideration is in the form of 7th convertible bond of Orbitech held by the buyers. transaction is expected to complete on July 30, 2024.
분석 기사 • Jul 12DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For GrowthDNA Link, Inc. ( KOSDAQ:127120 ) shares have had a really impressive month, gaining 27% after a shaky period...
New Risk • Jun 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩6.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Minor Risks Shareholders have been diluted in the past year (9.3% increase in shares outstanding). Market cap is less than US$100m (₩48.0b market cap, or US$34.9m).
Reported Earnings • Mar 22Full year 2023 earnings released: ₩323 loss per share (vs ₩460 loss in FY 2022)Full year 2023 results: ₩323 loss per share (improved from ₩460 loss in FY 2022). Revenue: ₩21.9b (up 29% from FY 2022). Net loss: ₩5.60b (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 19There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is UndemandingYou may think that with a price-to-sales (or "P/S") ratio of 2.6x DNA Link, Inc. ( KOSDAQ:127120 ) is definitely a...
공시 • Jan 25DNA Link, Inc. announced that it has received KRW 2 billion in funding from Orbitech Co., Ltd.On January 25, 2024, DNA Link, Inc. closed the transaction.
공시 • Jan 22DNA Link, Inc. announced that it expects to receive KRW 2 billion in funding from Orbitech Co., Ltd.DNA Link, Inc. announces private placement of series 10 Domestic bearer interest-unsecured private placement convertible bonds for a principal amount of KRW 2,000,000,000 on January 22, 2024. The bonds will bear a surface interest rate of 2% and interest rate to maturity of 4% and will mature on January 25, 2027. The bonds will convertible into 617,283 shares of the company at conversion price of KRW 3,240 per share at a 100% conversion rate. The transaction will include participation from returning investor, Orbitech Co., Ltd.
New Risk • Nov 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.1b free cash flow). Earnings have declined by 5.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.3% increase in shares outstanding). Market cap is less than US$100m (₩71.4b market cap, or US$55.0m).
New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.1b free cash flow). Earnings have declined by 5.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩64.1b market cap, or US$48.4m).
Reported Earnings • Apr 01Full year 2022 earnings released: ₩460 loss per share (vs ₩311 loss in FY 2021)Full year 2022 results: ₩460 loss per share (further deteriorated from ₩311 loss in FY 2021). Revenue: ₩17.0b (down 26% from FY 2021). Net loss: ₩7.78b (loss widened 53% from FY 2021). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
분석 기사 • Apr 19Is DNA Link (KOSDAQ:127120) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • Feb 23Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last YearSome DNA Link, Inc. ( KOSDAQ:127120 ) shareholders are probably rather concerned to see the share price fall 66% over...
Is New 90 Day High Low • Feb 17New 90-day low: ₩6,530The company is down 56% from its price of ₩14,850 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Jan 27New 90-day low: ₩7,280The company is down 67% from its price of ₩21,750 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period.
Is New 90 Day High Low • Jan 11New 90-day low: ₩7,740The company is down 71% from its price of ₩26,600 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 20% over the same period.
Is New 90 Day High Low • Dec 09New 90-day low: ₩12,000The company is down 42% from its price of ₩20,700 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.
공시 • Nov 27BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test act the Point of CareBASE10 Genetics and DNA Link announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings; Although Covid-19 deaths and new confirmed cases continue to rise across nursing homes in the US, many of those infected do recover. This has led to growing interest in the relationship between antibodies and their protective value whether generated by previous Covid-19 exposure or by a vaccine, once available.
Is New 90 Day High Low • Nov 16New 90-day low: ₩14,000The company is down 21% from its price of ₩17,700 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day high: ₩24,700The company is up 267% from its price of ₩6,730 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.